Results 131 to 140 of about 187,458 (237)
Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Background Mature B‐cell neoplasms chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and waldenström macroglobulinaemia (WM) are highly prevalent in older populations. Aims This study quantified the incidence, prevalence and relative survival/mortality rate in Australia for CLL/SS and WM and reported the past trends. Materials
Dieu Nguyen +6 more
wiley +1 more source
Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity [PDF]
, 2003 The Tec family member Bruton's tyrosine kinase (Btk) is a cytoplasmic protein tyrosine kinase that transduces signals from the pre-B and B cell receptor (BCR).
Dahlenborg, K. +4 more
core +1 more source
Overcoming challenges in CAR‐T therapy for malignancies: Mechanisms and strategies
Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.Chimeric antigen receptor T (CAR‐T) cell therapy faces three major challenges: tumour‐intrinsic resistance mechanisms, limitations in CAR‐T cell efficacy and immunosuppressive tumour microenvironment (TME) effects. Emerging strategies address these hurdles through precision targeting enhancement, optimised CAR‐T cell persistence/functionality and TME ...
Yushan Huang +7 more
wiley +1 more source
Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma
MicrobiologyOpen, Volume 15, Issue 1, February 2026.Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo +5 more
wiley +1 more source
Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
Frontiers in Immunology, 2021 C. I. Edvard Smith +3 more
doaj +1 more source
Mycoplasma pneumonia in a patient with X-linked agammaglobulinemia
BMC Infectious DiseasesBackground X-linked agammaglobulinemia (XLA), also referred to as Bruton’s tyrosine kinase deficiency, is a rare genetic disorder that affects the immune system.
Bowen Dai +15 more
doaj +1 more source
Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
ImmunoTargets and Therapy, 2021 Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School ...
Arneson LC, Carroll KJ, Ruderman EM
doaj
MedComm, Volume 7, Issue 2, February 2026.Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao +8 more
wiley +1 more source
Profound Sinoatrial Arrest Associated with Ibrutinib
Case Reports in Oncological Medicine, 2017 Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia.
Kanupriya Mathur +3 more
doaj +1 more source
Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.
American Journal of Physiology - Lung cellular and Molecular Physiology, 2018 Infection with seasonal influenza A virus (IAV) leads to lung inflammation and respiratory failure, a main cause of death in influenza-infected patients.
J. Florence +5 more
semanticscholar +1 more source